Human study PLS-00088

Changes in MOTS-c Level in the Blood of Pregnant Women with Metabolic Disorders.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

Changes in MOTS-c Level in the Blood of Pregnant Women with Metabolic Disorders.primary · Biology · 2021-10-12 · PMID 34681131 · DOI

Design and participants

Design: Cross-sectional study
Population: Pregnant women (healthy, obese, or with thyroid disorders including hypothyroidism) and their newborns (umbilical cord blood)
Conditions: pregnancy, obesity, hypothyroidism, thyroid disorders
Planned enrollment (registry): Not reported
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

The authors concluded (paraphrased): Authors concluded that MOTS-c blood levels change across physiological states, being higher in obese and lower in hypothyroid pregnancies, and that MOTS-c may in future become a tool against metabolic diseases such as obesity or type 2 diabetes.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

inappropriate endpoint: Only endogenous MOTS-c concentrations were measured. No administration of the compound and no clinical effect of it was studied.
abstract only: Only the abstract is available in the record. Sample sizes, methods and numeric results are not reported.
confounding: Groups were compared observationally, and the abstract reports no adjustment for confounders such as age or gestational age.
no control group: No MOTS-c was administered; the study compares endogenous levels across groups, so it cannot show any effect of the peptide.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves metabolic health: not eligible (not primary study) for “Insulin sensitivity, glucose control or body weight”
Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”

Where each value comes from

author_conclusion: PMID 34681131, abstract (last sentence) · extracted by AI (automated, not verified by a person) · abstract only
design: PMID 34681131, abstract (sentences 6-8) · extracted by AI (automated, not verified by a person) · abstract only
population: PMID 34681131, abstract (sentence 7) · extracted by AI (automated, not verified by a person) · abstract only

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).